Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access to Veliparib

NCT03123211 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03123211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03123211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access to Veliparib
Lead sponsor
AbbVie
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

high grade serous ovarian cancer, patients requiring veliparib suspension formulation, solid tumors with documented brca, bard, or palb or other acceptable dna mutations or anomalies that are scientifically sound, triple negative breast cancer (tnbc)